Colon News and Research

RSS

Good vitamin D status can prevent cancer, improve prognosis of several cancers

A good vitamin D status is beneficial both in cancer prevention and in the prognosis of several cancers, according to a new research review.

10 Jun 2020

New insights on DNA replication can help develop novel cancer treatments

A study by the Centre for Chromosome Biology at NUI Galway, Ireland, in partnership with the University of Zurich, has uncovered new insights into how the replication of DNA occurs which can be applied to help develop novel cancer treatments.

10 Jun 2020

High-salt diet may modulate the gut microbiome

Particularly in females with untreated hypertension, reducing salt intake to what's considered a healthier level appears to be good for both their gut microbiome and their blood pressure, scientists report.

9 Jun 2020

Opioid, sedative and antidepressant use prior to surgery leads to more complications

A study led by University of Kentucky Markey Cancer Center researchers showed that patients who already used opioids, sedatives or antidepressants prior to colorectal surgery experience significantly more complications post-surgery.

8 Jun 2020

New insights into how parenteral oil emulsions prevent liver disease in preterm babies

Infants born prematurely may require parenteral or intravenous nutrition to provide the necessary nourishment, as their digestive system is immature and cannot digest nutrients.

4 Jun 2020

Study explores the role of mi RNAs in anticancer effect exerted by physical activity

Volume 11, Issue 22 of Oncotarget reported that the goal of this study was to explore the involvement of mi RNAs in beneficial effects exerted by physical activity in breast cancer prevention.

3 Jun 2020

Tumors cause disruption of the immune system throughout the body, study finds

Cancer treatment has advanced with the advent of immunotherapies that, in some cancers, can overcome tumors' ability to evade the immune system by suppressing local immune responses.

3 Jun 2020

New guidelines improve outcomes in colon cancer patients

A new University of Kentucky Markey Cancer Center study finds that many Kentucky patients with colon cancer are not receiving the recommended standard of care therapy for their disease.

3 Jun 2020

SARS-CoV-2 infected patients who undergo surgery experience worse postoperative outcomes

Patients undergoing surgery after contracting coronavirus are at greatly increased risk of postoperative death, a new global study published in The Lancet reveals.

2 Jun 2020

Oral antidiabetics improve outcomes in diabetics with colorectal cancer

Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.

1 Jun 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Changes in gut mucus are linked to brain disorders

Mucus is the first line of defense against bad bacteria in our gut. But could it also be part of our defense against diseases of the brain?

29 May 2020

How comorbidities affect SARS-CoV-2 viral entry

Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.

28 May 2020

TissueGnostics achieves milestone in research community

TissueGnostics is pleased to announce achieving a new level of confidence within the international biomedical research community. As of May 2020, TissueGnostics has been referenced in over 1,500 individual research publications. High impact research made possible by TissueGnostics, emerging from 59 countries on 6 continents, results in a sum impact factor of 8,700.

From TissueGnostics 26 May 2020

ACE2 receptors for SARS-CoV-2 in human eye

Since its emergence in Wuhan, China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly over most of the world’s inhabited regions, causing millions of cases and hundreds of thousands of deaths. The primary symptoms of COVID-19, the disease caused by SARS-CoV-2, are fever, dry cough, and tiredness.

25 May 2020

Well-known cancer drugs may prevent SARS-CoV-2 viral replication say researchers

Researchers in Frankfurt, Germany, have described cell signaling events that occur when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells and have identified pathways that are essential for the virus to replicate.

17 May 2020

First detailed study of the epigenetic landscape of human tumor organoids

The researcher Manel Esteller performs the first massive epigenetic characterization in organoids or 3D cancer cultures and makes the data available to the research community to facilitate new findings on tumor development and progression.

15 May 2020

Potential targets discovered for COVID-19 therapy

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-2, the virus causing COVID-19 in people.

14 May 2020

Variations in genome’s 'dark matter' region can make patients susceptible to inflammatory diseases

A study led by researchers at the Babraham Institute in collaboration with the Wellcome Sanger Institute has uncovered how variations in a non-protein coding 'dark matter' region of the genome could make patients susceptible to complex autoimmune and allergic diseases such as inflammatory bowel disease.

14 May 2020

First detailed study of the epigenetic landscape of human tumor organoids

Frequently, promising cancer therapies fail when applied to patients in the real clinical setting. This occurs despite many of these new treatments demonstrating promising results at the preclinical stage in the lab.

13 May 2020